Global Photophobia Drug Market, By Causes Type (Migraine, Scleritis, Corneal Ulcer, Conjunctivitis, Dry Eyes, Others), Treatment Type (Medication, Surgery), Mechanism of Action Type (Serotonin (5-HT1B/1D) Receptor Agonist (Triptan), Calcitonin Gene-Related Peptide Receptor Antagonist, Acetylcholine Release Inhibitor and Others), Route of Administration (Oral, Topical, Injectable), End- User (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
The photophobia drug market is expected to gain market growth at a potential rate of 13.95% in the forecast period of 2021 to 2028. Rise in the ongoing clinical trial studies being carried out by many pharmaceuticals industries is the vital factor escalating the photophobia drug market growth.
Photophobia is also known as photosensitivity which is a type of condition in which people are intolerance of light. It can be direct sunlight or artificial light sources such as lamps and street lights. Photosensitivity also can be a symptom of underlying diseases such as migraine and dry eyes and due to the lack of eye pigment called albinism. Nearly all patients with migraine and dry eyes syndrome reported photophobia during headache episodes and subsequently impact on quality of life and social functioning. The patients with photophobia avoid light because of pain or discomfort to the eyes.
Rise in exposure to certain toxin or change in environment may increase the migraine condition will uplift the market growth, also rise in the rapid adoption of newer formulations and novel dosage forms, rise in the prevalence rate of photophobia worldwide, rise in the population of photophobia worldwide and emergence of drugs used in the treatment of risk associated with photophobia condition such as migraine and dry eyes are some of the crucial factors among others driving the photophobia drug market growth. Moreover, rise in the research and development activities in the market, increase in the healthcare outcomes and rise in the demand from emerging economies will further create new opportunities for the photophobia drug market in the forecast period of 2021-2028.
However, effective treatment is either unavailable or unaffordable and inadequate knowledge about photophobia in some developing countries are the major factors among others acting as restraints, while patent expiry from many companies and introduction of generic drugs of branded version will further challenge the photophobia drug market in the forecast period mentioned above.
This photophobia drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the photophobia drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Photophobia Drug Market Scope and Market Size
The photophobia drug market is segmented on the basis of causes type, treatment type, mechanism of action type, route of administration and end-user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of causes type, the photophobia drug market is segmented into migraine, scleritis, corneal ulcer, conjunctivitis, dry eyes and others.
- Based on treatment type, the photophobia drug market is segmented into medication and surgery.
- Based on mechanism of action type, the photophobia drug market is segmented into serotonin (5-HT1B/1D) receptor agonist (triptan), calcitonin gene-related peptide receptor antagonist, acetylcholine release inhibitor and others. Serotonin (5-HT1B/1D) receptor agonist (triptan) has been further segmented into sumatriptan. Calcitonin gene-related peptide receptor antagonist has been further segmented into fremanezumab, erenumab and galcanezumab. Acetylcholine release inhibitor has been further segmented into onabotulinumtoxina.
- Based on route of administration, the photophobia drug market is segmented into oral, topical and injectable.
- The photophobia drug market is also segmented on the basis of end-user into hospitals, homecare, specialty clinics and others.
Photophobia Drug Market Country Level Analysis
The photophobia drug market is analysed and market size information is provided by country, causes type, treatment type, mechanism of action type, route of administration and end-user as referenced above.
The countries covered in the photophobia drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the photophobia drug market due to increase in the rapid adoption of newer formulations and novel dosage forms, increase in the prevalence rate of photophobia worldwide and rise in the population of photophobia worldwide and emergence of drugs used in the treatment of risk associated with photophobia condition such as migraine and dry eyes in this region. Asia-Pacific is the expected region in terms of growth in photophobia drug market due to rise in the rapid adoption of newer formulations and novel dosage forms in this region.
The country section of the photophobia drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The photophobia drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Photophobia Drug Market Share Analysis
The photophobia drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to photophobia drug market.
The major players covered in the photophobia drug market report are Sun Pharmaceutical Industries Ltd, Pfizer Inc, GlaxoSmithKline plc, Allergan, Amgen Inc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Novartis AG, Johnson & Johnson Services, Inc., Bausch Health, Merck & Co., Inc, Alder Biopharmaceuticals Inc, Zogenix, RedHill, Eisai Co., Ltd, Ionis Pharmaceuticals, Inc, Biofrontera AG , Biohaven Pharmaceuticals, Achelios and Dr. Reddy’s Laboratories Ltd market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.